公开(公告)号：US20180072694A1

公开(公告)日：2018-03-15

申请号：US15561613

申请日：2016-03-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Keiko Kakegawa ,  Zenichi IKEDA ,  Minoru SASAKI ,  Fumiaki KIKUCHI ,  Yoichi NISHIKAWA

IPC: C07D307/79 ,  C07D413/04 ,  C07F9/655

CPC classification number: C07D307/79 ,  A61K31/343 ,  A61K31/422 ,  A61K31/665 ,  A61P3/04 ,  A61P3/10 ,  C07D413/04 ,  C07F9/38 ,  C07F9/65517

Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. Specifically, the present invention relates to a compound represented by the formula (I) or a salt thereof, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like [in the formula, each symbol is as defined in the specification].

公开(公告)号：US20160355494A1

公开(公告)日：2016-12-08

申请号：US15117538

申请日：2015-02-12

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Minoru SASAKI ,  Keiko KAKEGAWA ,  Fumiaki KIKUCHI ,  Zenichi IKEDA ,  Yoichi NISHIKAWA

IPC: C07D307/81

CPC classification number: C07D307/81

Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.

公开(公告)号：US20220289679A1

公开(公告)日：2022-09-15

申请号：US17630442

申请日：2020-07-28

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuta TANAKA ,  Yuta TANAKA ,  Keiko KAKEGAWA ,  Takahito KASAHARA ,  Fumiaki KIKUCHI ,  Takeshi YAMAMOTO ,  Tomohiro OHASHI ,  Zenichi IKEDA ,  Florian PUENNER ,  Minoru NAKAMURA ,  Kazuaki TAKAMI ,  Masataka MURAKAMI ,  Masaki DAINI ,  Masaki SETO ,  Satoshi MIKAMI ,  Minoru SASAKI

IPC: C07D213/82 ,  C07D401/12 ,  C07D471/04 ,  C07D413/12 ,  C07D405/14 ,  C07D401/14 ,  C07D237/14 ,  C07D405/12

Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20160347724A1

公开(公告)日：2016-12-01

申请号：US15117539

申请日：2015-02-12

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Zenichi IKEDA ,  Minoru SASAKI ,  Keiko KAKEGAWA ,  Fumiaki KIKUCHI ,  Yoichi NISHIKAWA

IPC: C07D261/04 ,  C07D413/10

CPC classification number: C07D261/04 ,  C07D413/10

Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.

公开(公告)号：US20220274982A1

公开(公告)日：2022-09-01

申请号：US17630840

申请日：2020-07-28

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuta TANAKA ,  Yuta TANAKA ,  Fumiaki KIKUCHI ,  Takeshi YAMAMOTO ,  Minoru NAKAMURA ,  Kazuaki TAKAMI ,  Masataka MURAKAMI ,  Masaki DAINI ,  Yasufumi WADA ,  Keiko KAKEGAWA ,  Takahito KASAHARA ,  Tomohiro OHASHI ,  Junsi WANG ,  Zenichi IKEDA ,  Florian PUENNER ,  Masaki SETO ,  Satoshi MIKAMI ,  Minoru SASAKI

IPC: C07D471/04

Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20190135799A1

公开(公告)日：2019-05-09

申请号：US16049359

申请日：2018-07-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masahiro ITO ,  Hideyuki SUGIYAMA ,  Osamu KUBO ,  Fumiaki KIKUCHI ,  Takeshi YASUI ,  Keiko KAKEGAWA ,  Zenichi IKEDA ,  Tohru MIYAZAKI ,  Yasuyoshi ARIKAWA ,  Tomohiro OKAWA ,  Jinichi YONEMORI ,  Akinori TOITA ,  Takuto KOJIMA ,  Yasutomi ASANO ,  Ayumu SATO ,  Hironobu MAEZAKI ,  Shinobu SASAKI ,  Hironori KOKUBO ,  Misaki HOMMA ,  Minoru SASAKI ,  Yasuhiro IMAEDA

IPC: C07D413/14 ,  C07D471/04 ,  A61P25/28 ,  C07D413/04 ,  C07D417/14

CPC classification number: C07D413/14 ,  A61P25/28 ,  C07D413/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20170349605A1

公开(公告)日：2017-12-07

申请号：US15539607

申请日：2015-12-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Minoru SASAKI ,  Fumiaki KIKUCHI ,  Zenichi IKEDA ,  Keiko KAKEGAWA ,  Yoichi NISHIKAWA ,  Shigekazu SASAKI ,  Koichiro FUKUDA ,  Kazuaki TAKAMI ,  Yoshihiro BANNO ,  Masahiro KAMAURA

IPC: C07D495/04 ,  C07D491/044 ,  C07D413/06 ,  C07D323/00 ,  C07D313/00 ,  C07D321/12 ,  C07D321/00 ,  C07D313/20 ,  C07D493/04 ,  C07D405/06

CPC classification number: C07D495/04 ,  A61K31/365 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/422 ,  A61K31/662 ,  C07D313/00 ,  C07D313/20 ,  C07D321/00 ,  C07D321/12 ,  C07D323/00 ,  C07D405/06 ,  C07D409/12 ,  C07D413/06 ,  C07D491/044 ,  C07D493/04 ,  C07F9/655

Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].

公开(公告)号：US20220098180A1

公开(公告)日：2022-03-31

申请号：US17426971

申请日：2020-01-29

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masahiro ITO ,  Takeshi YAMAMOTO ,  Keiko KAKEGAWA ,  Hideyuki SUGIYAMA ,  Tohru MIYAZAKI ,  Yasuyoshi ARIKAWA ,  Tomohiro OKAWA ,  Jinichi YONEMORI ,  Osamu KUBO ,  Akinori TOITA ,  Takuto KOJIMA ,  Fumiaki KIKUCHI ,  Minoru SASAKI ,  Misaki HOMMA ,  Yasuhiro IMAEDA ,  Hironobu MAEZAKI ,  Shiinobu SASAKI ,  Ayumu SATO ,  Hirotaka KAMITANI ,  Yasutomi ASANO ,  Hironori KOKUBO ,  Masato YOSHIKAWA

IPC: C07D413/10 ,  C07D271/06 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20220089525A1

公开(公告)日：2022-03-24

申请号：US17310164

申请日：2020-01-23

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yuya OGURO ,  Makoto KAMATA ,  Satoshi MIKAMI ,  Shinji MORIMOTO ,  Sachie TAKASHIMA ,  Masaki DAINI ,  Osamu KUBO ,  Fumiaki KIKUCHI ,  Akinori TOITA ,  Florian PUENNER ,  Takahito KASAHARA ,  Masataka MURAKAMI ,  Shuhei IKEDA ,  Fumie YAMAGUCHI ,  Minoru NAKAMURA ,  Takafumi YUKAWA

IPC: C07C255/60 ,  C07D213/82 ,  C07D401/12 ,  C07D409/12 ,  A61P25/06 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00

Abstract: A heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like is provided. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20210087186A1

公开(公告)日：2021-03-25

申请号：US16961476

申请日：2019-01-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuta TANAKA ,  Tomohiro OHASHI ,  Zenichi IKEDA ,  Yuta TANAKA ,  Florian PÜNNER ,  Takeshi YAMAMOTO ,  Keiko KAKEGAWA ,  Fumiaki KIKUCHI ,  Nao MORISHITA ,  Takahito KASAHARA ,  Masaki SETO ,  Minoru NAKAMURA ,  Kazuaki TAKAMI ,  Masataka MURAKAMI ,  Masaki DAINI ,  Satoshi MIKAMI ,  Minoru SASAKI

IPC: C07D471/04 ,  C07D495/04 ,  C07D487/04 ,  C07D491/048 ,  C07D519/00

Abstract: The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I) wherein each symbol is as described in the specification, or a salt thereof.